Temozolomide chemotherapy in recurrent oligodendroglioma.
The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.
van den Bent
M J
MJ
Department of Neuro-Oncology, University Hospital Rotterdam/Rotterdam Cancer Center, the Netherlands. bent@neuh.azr.nl
Keime-Guibert
F
F
Brandes
A A
AA
Taphoorn
M J
MJ
Kros
J M
JM
Eskens
F A
FA
Carpentier
A F
AF
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000503:physiopathology*; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000503:physiopathology*; D000077204:Temozolomide; D013997:Time Factors
D000970:Antineoplastic Agents; D003606:Dacarbazine; D000077204:Temozolomide